<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2" exact="Infection" post="BhattiJasvinder Singhjasvinder.bhatti@cup.edu.in1BhattiGurjit Kaurbhattigk@yahoo.com2KhullarNainanaina306@gmail.com3ReddyArubala P.arubala.reddy@ttuhsc.edu4http://orcid.org/0000-0002-9560-9948ReddyP. Hemachandrahemachandra.reddy@ttuhsc.edu56789[1], grid.428366.d0000 0004 1773 9952Department"/>
 <result pre="of Human Genetics and Molecular Medicine, School of Health Sciences," exact="Central" post="University of Punjab, [2], grid.448792.40000 0004 4678 9721Department of"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="The whole world is currently facing a pandemic of an" exact="infectious disease" post="known as novel coronavirus disease-2019 (COVID-19) caused by severe"/>
 <result pre="whole world is currently facing a pandemic of an infectious" exact="disease" post="known as novel coronavirus disease-2019 (COVID-19) caused by severe"/>
 <result pre="disease known as novel coronavirus disease-2019 (COVID-19) caused by severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2)Â . This outbreak emerged unexpectedly"/>
 <result pre="known as novel coronavirus disease-2019 (COVID-19) caused by severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2)Â . This outbreak emerged unexpectedly and"/>
 <result pre="as novel coronavirus disease-2019 (COVID-19) caused by severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2)Â . This outbreak emerged unexpectedly and imposed"/>
 <result pre="with preexisting health conditions. However, the potential pathogenesis of SARS-CoV-2" exact="infection" post="in humans is still unknown. The dysregulated/exuberant immune response"/>
 <result pre="the development of vaccines or anti-viral drug molecules against SARS-CoV-2" exact="infection" post="in humans. Keywords Novel coronavirus disease COVID-19 SARS-CoV-2 Anti-viral"/>
 <result pre="drug molecules against SARS-CoV-2 infection in humans. Keywords Novel coronavirus" exact="disease" post="COVID-19 SARS-CoV-2 Anti-viral drugs Vaccine Clinical trials Funding http://dx.doi.org/10.13039/100000002National"/>
 <result pre="three coronavirus (CoV) outbreaks occurred in the world [1]: severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002 [2, 3], Middle"/>
 <result pre="coronavirus (CoV) outbreaks occurred in the world [1]: severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002 [2, 3], Middle East"/>
 <result pre="(CoV) outbreaks occurred in the world [1]: severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002 [2, 3], Middle East respiratory"/>
 <result pre="respiratory syndrome coronavirus (SARS-CoV) in 2002 [2, 3], Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012 [4], and SARS CoV-2"/>
 <result pre="syndrome coronavirus (SARS-CoV) in 2002 [2, 3], Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012 [4], and SARS CoV-2 in"/>
 <result pre="2003 [6, 7]. MERS-CoV was first reported to cause human" exact="infection" post="in Saudi Arabia in 2012, where it remains a"/>
 <result pre="public health concern, and spread over 27 countries, infecting a" exact="total" post="of 2,494 individuals and claiming 868 (34.77%) fatalities during"/>
 <result pre="December 2019 [4, 7, 8]. The recent outbreak of coronavirus" exact="disease" post="2019 (COVID-19) started in December 2019 in Wuhan City"/>
 <result pre="transmission across the world [9â€&quot;11]. It continues to cause severe" exact="infections" post="in humans, posing significant threats to global public health."/>
 <result pre="age range of the infected persons. COVID-19 primarily spread through" exact="respiratory" post="droplets. The manifestation of SARS-CoV-2 infections ranges from fever,"/>
 <result pre="COVID-19 primarily spread through respiratory droplets. The manifestation of SARS-CoV-2" exact="infections" post="ranges from fever, cough, shortness of breath, fatigue, and,"/>
 <result pre="breath, fatigue, and, in a small population of patients, gastrointestinal" exact="infection" post="symptoms to acute respiratory distress and pneumonia [15â€&quot;17]. The"/>
 <result pre="in a small population of patients, gastrointestinal infection symptoms to" exact="acute" post="respiratory distress and pneumonia [15â€&quot;17]. The loss of taste"/>
 <result pre="a small population of patients, gastrointestinal infection symptoms to acute" exact="respiratory" post="distress and pneumonia [15â€&quot;17]. The loss of taste (ageusia)"/>
 <result pre="of patients, gastrointestinal infection symptoms to acute respiratory distress and" exact="pneumonia" post="[15â€&quot;17]. The loss of taste (ageusia) and loss of"/>
 <result pre="presence of ageusia and anosmia in the patients with COVID-19" exact="infection" post="[18â€&quot;20]. The reproductive number of SARS-CoV-2 infection is estimated"/>
 <result pre="patients with COVID-19 infection [18â€&quot;20]. The reproductive number of SARS-CoV-2" exact="infection" post="is estimated to be 2â€&quot;3 [11], and the elderly"/>
 <result pre="and the elderly people with underlying complications such as diabetes," exact="heart" post="disease, lung disease, cancer, etc. are more susceptible to"/>
 <result pre="elderly people with underlying complications such as diabetes, heart disease," exact="lung disease," post="cancer, etc. are more susceptible to severe infection and"/>
 <result pre="disease, lung disease, cancer, etc. are more susceptible to severe" exact="infection" post="and fatality [21â€&quot;24]. Currently, there is no clinically approved"/>
 <result pre="treating COVID-19 patients with the available drugs used in other" exact="respiratory" post="infections. However, several potent candidates of antivirals and repurposed"/>
 <result pre="a 5.9% mortality rate estimated by the WHO. Although the" exact="disease" post="is now better contained in the suspected origin, the"/>
 <result pre="few months which accounts for around one quarter of the" exact="total" post="number of infections worldwide. The USA, Brazil, and India"/>
 <result pre="accounts for around one quarter of the total number of" exact="infections" post="worldwide. The USA, Brazil, and India are the most"/>
 <result pre="of the world followed by the USA. However, the actual" exact="total" post="death toll may be higher than the number of"/>
 <result pre="be higher than the number of confirmed deaths, due to" exact="limited" post="testing and problems in the attribution of the cause"/>
 <result pre="of death and the difference between reported confirmed deaths and" exact="total" post="deaths that varies by country to country. Surprisingly, men"/>
 <result pre="within the Nidovirales order and are classified into 4 genera:" exact="Alpha" post="(Î±), Beta (Î²), Gamma (Î³), and Delta (Î´) coronavirus."/>
 <result pre="and are classified into 4 genera: Alpha (Î±), Beta (Î²)," exact="Gamma" post="(Î³), and Delta (Î´) coronavirus. They are single-stranded RNA"/>
 <result pre="to enter the target cell, and mainly spreads through the" exact="respiratory" post="tract. ACE2 enzyme is involved in the regulation of"/>
 <result pre="intestines. SARS-CoV-2 binds to ACE2 through spike proteins. However, the" exact="external" post="subdomain of the spikeâ€™s receptor-binding domain of SARS-CoV-2 shares"/>
 <result pre="and MERS-CoV Current Scenario of Possible Therapeutic Drugs Against SARS-CoV-2" exact="Infection" post="To date, we do not have any clinically approved"/>
 <result pre="etc. are used to restrict the further transmission of SARS-CoV-2" exact="infection" post="across the world. Several pharmacological treatment possibilities are being"/>
 <result pre="ritonavir, etc. previously used for SARS and MERS or other" exact="viral" post="infections is now being followed to treat SARS-CoV-2 infection"/>
 <result pre="etc. previously used for SARS and MERS or other viral" exact="infections" post="is now being followed to treat SARS-CoV-2 infection and"/>
 <result pre="other viral infections is now being followed to treat SARS-CoV-2" exact="infection" post="and might have gained significant improvement in pneumonia-associated symptoms"/>
 <result pre="coronaviruses [30, 39â€&quot;41]. However, it was less effective against ebolavirus" exact="infections" post="in humans [42]. Recently, clinical trials of remdesivir against"/>
 <result pre="Interventions Locations 1 Maternal-Foetal Transmission of SARS-Cov-2 Recruiting Maternal fetal" exact="infection" post="transmission COVID-19 SARS-CoV 2 Diagnostic test: diagnosis of SARS-Cov2"/>
 <result pre="Comparison of the Efficacy of Rapid Tests to Identify COVID-19" exact="Infection" post="(CATCh COVID-19) Not yet recruiting COVID-19 Diagnostic test: diagnostic"/>
 <result pre="Not yet recruiting COVID-19 Diagnostic test: diagnostic tests for COVID-19" exact="infection" post="4 The Role of a Private Hospital in Hong"/>
 <result pre="Study Evaluating the Safety and Efficacy of Autologous Non-hematopoietic Peripheral" exact="Blood" post="Stem Cells in Covid-19 Completed Coronavirus disease 2019 (COVID-19)"/>
 <result pre="Autologous Non-hematopoietic Peripheral Blood Stem Cells in Covid-19 Completed Coronavirus" exact="disease" post="2019 (COVID-19) Biological: autologous non-hematopoietic peripheral blood stem cells"/>
 <result pre="in Covid-19 Completed Coronavirus disease 2019 (COVID-19) Biological: autologous non-hematopoietic" exact="peripheral" post="blood stem cells (NHPBSC) Drug: COVID-19 standard care â€¢"/>
 <result pre="RealDetect RT-PCR Kit for COVID-19 detection â€¢ Institute of Epidemiology," exact="Disease" post="Control and Research (IEDCR), Mohakhali, Dhaka (for sample collection"/>
 <result pre="Bangladesh 8 Diagnostic Value of Patient-Reported and Clinically Verified Olfactory" exact="Disorders" post="(COVID-19) Completed COVID-19 Biological: reporting of anosmia, ageusia, and"/>
 <result pre="clinical symptoms â€¢ Uhmontpellier, Montpellier, France 9 Smell and Taste" exact="Disorders" post="in COVID-19 Patients Recruiting COVID-19 Other: investigation of smell"/>
 <result pre="taste disorders â€¢ ASST Monza-Ospedale San Gerardo, Monza, Italy 10" exact="Neonatal" post="Complications of Coronavirus Disease (COVID-19) Recruiting Neonatal COVID-19 disease"/>
 <result pre="Monza-Ospedale San Gerardo, Monza, Italy 10 Neonatal Complications of Coronavirus" exact="Disease" post="(COVID-19) Recruiting Neonatal COVID-19 disease Other: no interventionâ€&quot;exposure is"/>
 <result pre="Monza, Italy 10 Neonatal Complications of Coronavirus Disease (COVID-19) Recruiting" exact="Neonatal" post="COVID-19 disease Other: no interventionâ€&quot;exposure is to COVID-19 â€¢"/>
 <result pre="10 Neonatal Complications of Coronavirus Disease (COVID-19) Recruiting Neonatal COVID-19" exact="disease" post="Other: no interventionâ€&quot;exposure is to COVID-19 â€¢ Imperial College,"/>
 <result pre="is to COVID-19 â€¢ Imperial College, London, UK 11 COVID-19" exact="Infection" post="in Patients with Hepatocellular Carcinoma Recruiting Hepatocellular carcinoma COVID-19"/>
 <result pre="Imperial College, London, UK 11 COVID-19 Infection in Patients with" exact="Hepatocellular" post="Carcinoma Recruiting Hepatocellular carcinoma COVID-19 Diagnostic test: nasopharyngeal COVID-19"/>
 <result pre="College, London, UK 11 COVID-19 Infection in Patients with Hepatocellular" exact="Carcinoma" post="Recruiting Hepatocellular carcinoma COVID-19 Diagnostic test: nasopharyngeal COVID-19 RT-PCR"/>
 <result pre="UK 11 COVID-19 Infection in Patients with Hepatocellular Carcinoma Recruiting" exact="Hepatocellular carcinoma" post="COVID-19 Diagnostic test: nasopharyngeal COVID-19 RT-PCR â€¢ CHU Amiens,"/>
 <result pre="11 COVID-19 Infection in Patients with Hepatocellular Carcinoma Recruiting Hepatocellular" exact="carcinoma" post="COVID-19 Diagnostic test: nasopharyngeal COVID-19 RT-PCR â€¢ CHU Amiens,"/>
 <result pre="Neurological Patients Not yet recruiting Neurological diseases or conditions Stroke," exact="acute" post="Seizure disorder Diagnostic test: COVID-19 swap test PCR â€¢"/>
 <result pre="Hospital West Jutland, Hostebro, Holstebro, DK, Denmark â€¢ Regional Hospital" exact="Central" post="Jutland, Viborg, Viborg, DK, Denmark 13 Frailty in Elderly"/>
 <result pre="Mississippi Medical Center, Jackson, MS, USA 15 COVID-19 in the" exact="Swedish" post="ICU-Cohort: Risk Factors of Critical Care Admission and Intensive"/>
 <result pre="NC, USA 17 Rapid Diagnostic Test for COVID-19 Based on" exact="Antibody" post="Detection (YCOVID) Active, not recruiting COVID-19 Diagnostic test: ELISA"/>
 <result pre="and Treatment of COVID-19 Complications Enrolling by invitation COVID-19 Coronavirus" exact="infection" post="SARS-CoV-2 Complications Other: complex diagnostic panel â€¢ Silesian Centre"/>
 <result pre="SARS-CoV-2 Complications Other: complex diagnostic panel â€¢ Silesian Centre for" exact="Heart Disease," post="Zabrze, Silesia, Poland 19 COVID19-Convalescent Plasma for Treating Patients"/>
 <result pre="COVID19-Convalescent Plasma for Treating Patients with Active Symptomatic COVID 19" exact="Infection" post="(FALP-COVID) Recruiting COVID-19 infection Cancer patients General population Biological:"/>
 <result pre="Patients with Active Symptomatic COVID 19 Infection (FALP-COVID) Recruiting COVID-19" exact="infection" post="Cancer patients General population Biological: convalescent plasma from COVID-19"/>
 <result pre="with Active Symptomatic COVID 19 Infection (FALP-COVID) Recruiting COVID-19 infection" exact="Cancer" post="patients General population Biological: convalescent plasma from COVID-19 donors"/>
 <result pre="Symptomatic COVID 19 Infection (FALP-COVID) Recruiting COVID-19 infection Cancer patients" exact="General" post="population Biological: convalescent plasma from COVID-19 donors â€¢ Fundacion"/>
 <result pre="SARS-CoV-2 â€¢ Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark 23" exact="Viral" post="Infection and Respiratory Illness Universal Study [VIRUS]: COVID-19 Registry"/>
 <result pre="â€¢ Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark 23 Viral" exact="Infection" post="and Respiratory Illness Universal Study [VIRUS]: COVID-19 Registry Recruiting"/>
 <result pre="University Hospital of Copenhagen, Copenhagen, Denmark 23 Viral Infection and" exact="Respiratory" post="Illness Universal Study [VIRUS]: COVID-19 Registry Recruiting Coronavirus Other:"/>
 <result pre="San Gerardo, Monza, Italy 25 Characteristics and Outcome of Coronavirus" exact="Disease" post="2019 (COVID-19) in Egypt Not yet recruiting Characteristic diseases"/>
 <result pre="Characteristic diseases Outcome, fatal Other: follow-up 26 Detection of Anti-COVID-19" exact="Antibody" post="Levels in an Hospital Population Recruiting COVID-19 Diagnostic test:"/>
 <result pre="with COVID-19: a Pilot Study Not yet recruiting Coronavirus Coronavirus" exact="infection" post="Drug: plasma â€¢ Universidad del Rosario, Bogota, Cundinamarca, Colombia"/>
 <result pre="Label, Parallel, Controlled Clinical Study Not yet recruiting Coronavirus Coronavirus" exact="infection" post="Drug: plasma Drug: hydroxychloroquine â€¢ Universidad del Rosario, Bogota,"/>
 <result pre="COVID-19 Hosts - Genetic Cause Relating to the Course of" exact="Disease" post="Progression Not yet recruiting COVID-19 Genetic: whole genome analysis"/>
 <result pre="genome analysis Genetic: T cell receptor (TCR) repertoire Genetic: SARS-CoV-2" exact="viral" post="composition 38 Beaumont Health Large-Scale Automated Serologic Testing for"/>
 <result pre="Health Large-Scale Automated Serologic Testing for COVID-19 Recruiting COVID-19 Coronavirus" exact="infection" post="Severe acute respiratory syndrome coronavirus 2 Diagnostic test: EUROIMMUN"/>
 <result pre="Large-Scale Automated Serologic Testing for COVID-19 Recruiting COVID-19 Coronavirus infection" exact="Severe" post="acute respiratory syndrome coronavirus 2 Diagnostic test: EUROIMMUN assay"/>
 <result pre="Automated Serologic Testing for COVID-19 Recruiting COVID-19 Coronavirus infection Severe" exact="acute" post="respiratory syndrome coronavirus 2 Diagnostic test: EUROIMMUN assay â€¢"/>
 <result pre="Serologic Testing for COVID-19 Recruiting COVID-19 Coronavirus infection Severe acute" exact="respiratory" post="syndrome coronavirus 2 Diagnostic test: EUROIMMUN assay â€¢ Beaumont"/>
 <result pre="Testing for COVID-19 Recruiting COVID-19 Coronavirus infection Severe acute respiratory" exact="syndrome" post="coronavirus 2 Diagnostic test: EUROIMMUN assay â€¢ Beaumont Health"/>
 <result pre="Royal Oak, MI, USA 39 Assessment of Obstetric, Fetal and" exact="Neonatal" post="Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic Recruiting"/>
 <result pre="Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic Recruiting" exact="Pregnancy" post="Diagnostic test: COVID 19 diagnostic test by PCR â€¢"/>
 <result pre="PCR â€¢ University Hospital of Toulouse, Toulouse, France 40 Minimal" exact="Invasive" post="Autopsies to Investigate Changes in Deceased COVID-19 Patients Recruiting"/>
 <result pre="Shams University, Cairo, Egypt 42 Clinical Characteristics and Outcomes of" exact="Pediatric" post="COVID-19 Recruiting COVID-19 SARS-CoV-2 infection Pediatric ALL Pneumonia, viral"/>
 <result pre="Clinical Characteristics and Outcomes of Pediatric COVID-19 Recruiting COVID-19 SARS-CoV-2" exact="infection" post="Pediatric ALL Pneumonia, viral Pandemic response Other: exposure (not"/>
 <result pre="Characteristics and Outcomes of Pediatric COVID-19 Recruiting COVID-19 SARS-CoV-2 infection" exact="Pediatric" post="ALL Pneumonia, viral Pandemic response Other: exposure (not intervention)â€&quot;SARS-CoV-2"/>
 <result pre="of Pediatric COVID-19 Recruiting COVID-19 SARS-CoV-2 infection Pediatric ALL Pneumonia," exact="viral" post="Pandemic response Other: exposure (not intervention)â€&quot;SARS-CoV-2 infection â€¢ University"/>
 <result pre="Pediatric ALL Pneumonia, viral Pandemic response Other: exposure (not intervention)â€&quot;SARS-CoV-2" exact="infection" post="â€¢ University of Calgary/Alberta Childrenâ€™s Hospital, Calgary, Alberta, Canada"/>
 <result pre="Tepecik Training and Research Hospital, Izmir, Izmir, Konak, Turkey 47" exact="Antibody" post="Based Tests for SARSCOV-2 COVID-19-Evaluation of Patients and Healthcare"/>
 <result pre="Hospital, North York, Ontario, Canada â€¢ The University of Ottawa" exact="Heart" post="Institute, Ottawa, Ontario, Canada 49 Classification of COVID-19 Infection"/>
 <result pre="Ottawa Heart Institute, Ottawa, Ontario, Canada 49 Classification of COVID-19" exact="Infection" post="in Posteroanterior Chest X-rays Completed COVID-19 Device: CovX â€¢"/>
 <result pre="At Risk Population (SHARP) Against COVID-19 Not yet recruiting Coronavirus" exact="infection" post="Hydroxychloroquine adverse reaction Drug: hydroxychloroquine sulfate 200Â mg (mg)"/>
 <result pre="Pharmacology Ltd. 1a Newcomen St, London Bridge, London, UK 53" exact="Pulmonary" post="Optical Coherence Tomography in COVID-19 Patients Recruiting COVID-19 Pulmonary"/>
 <result pre="53 Pulmonary Optical Coherence Tomography in COVID-19 Patients Recruiting COVID-19" exact="Pulmonary" post="embolism Diagnostic test: optical coherence tomography (OCT) â€¢ Incor"/>
 <result pre="embolism Diagnostic test: optical coherence tomography (OCT) â€¢ Incor -" exact="Heart" post="Institute - University of Sao Paulo, SÃ£o Paulo, Brazil"/>
 <result pre="Hospital, Beijing, Beijing, China 55 Descriptive and Retrospective Analysis of" exact="Acute" post="Myocarditis Associated with Pandemic COVID-19 in Children Not yet"/>
 <result pre="Delhi, India 58 Convalescent Plasma In ICU Patients With COVID-19-Induced" exact="Respiratory" post="Failure Recruiting COVID-19 SARS-CoV-2 Biological: multiple doses of anti-SARS-CoV-2"/>
 <result pre="India 58 Convalescent Plasma In ICU Patients With COVID-19-Induced Respiratory" exact="Failure" post="Recruiting COVID-19 SARS-CoV-2 Biological: multiple doses of anti-SARS-CoV-2 convalescent"/>
 <result pre="â€¢ Johns Hopkins University, Baltimore, MD, USA 59 Immunoglobulin G" exact="Antibody" post="Immune Response Profile Following Infection with SARS-CoV-2 in COVID-19"/>
 <result pre="MD, USA 59 Immunoglobulin G Antibody Immune Response Profile Following" exact="Infection" post="with SARS-CoV-2 in COVID-19 Egyptian Patients Recruiting COVID-19 â€¢"/>
 <result pre="of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19" exact="Infection" post="Recruiting Severe acute respiratory syndrome coronavirus 2 Biological: COVID-19"/>
 <result pre="COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection Recruiting" exact="Severe" post="acute respiratory syndrome coronavirus 2 Biological: COVID-19 convalescent plasma"/>
 <result pre="Convalescent Plasma in Patients Admitted for COVID-19 Infection Recruiting Severe" exact="acute" post="respiratory syndrome coronavirus 2 Biological: COVID-19 convalescent plasma â€¢"/>
 <result pre="Plasma in Patients Admitted for COVID-19 Infection Recruiting Severe acute" exact="respiratory" post="syndrome coronavirus 2 Biological: COVID-19 convalescent plasma â€¢ Hospital"/>
 <result pre="in Patients Admitted for COVID-19 Infection Recruiting Severe acute respiratory" exact="syndrome" post="coronavirus 2 Biological: COVID-19 convalescent plasma â€¢ Hospital ClÃ­nico"/>
 <result pre="Will Hydroxychloroquine Impede or Prevent COVID-19 Recruiting COVID-19 Coronavirus Coronavirus" exact="infections" post="SARS-CoV-2 Drug: Hydroxychloroquineâ€&quot;daily dosing Drug: hydroxychloroquineâ€&quot;weekly dosing Other: placebo"/>
 <result pre="of COVID-19: a Randomized Control Trial Not yet recruiting SARS-CoV-2" exact="infections" post="COVID-19 Drug: oral â€¢ Assistant Professor Subsai Kongsaengdao, Bangkok,"/>
 <result pre="France 64 Effects on the Qt Interval of COVID-19 Coronavirus" exact="Infection" post="Recruiting Coronavirus infection Intensive care patients â€¢ Servicio de"/>
 <result pre="on the Qt Interval of COVID-19 Coronavirus Infection Recruiting Coronavirus" exact="infection" post="Intensive care patients â€¢ Servicio de Anestesia, Hospital General"/>
 <result pre="Coronavirus infection Intensive care patients â€¢ Servicio de Anestesia, Hospital" exact="General" post="Universitario Gregorio MaraÃ±on, Madrid, Spain 65 COVID-19 Convalescent Plasma"/>
 <result pre="COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients with" exact="Pneumonia" post="Caused by SARS- CoV-2 Recruiting COVID-19 Biological: COVID-19 convalescent"/>
 <result pre="Transplant Group, Paris, France 67 Testing the Accuracy of a" exact="Digital" post="Test to Diagnose Covid-19 Recruiting COVID-19 Diagnostic test: COVID-19"/>
 <result pre="College London, London, United Kingdom 68 Clinical Trial of Allogeneic" exact="Mesenchymal" post="Cells from Umbilical Cord Tissue in Patients with COVID-19"/>
 <result pre="United Kingdom 68 Clinical Trial of Allogeneic Mesenchymal Cells from" exact="Umbilical" post="Cord Tissue in Patients with COVID-19 Recruiting COVID Biological:"/>
 <result pre="Spain â€¢ Complejo Universitario La Paz, Madrid, Spain 69 The" exact="Heart" post="Hive COVID-19 Study Not yet recruiting COVID-19 Cardiomyopathies Other:"/>
 <result pre="69 The Heart Hive COVID-19 Study Not yet recruiting COVID-19" exact="Cardiomyopathies" post="Other: COVID-19 experience surveys â€¢ Imperial College London, London,"/>
 <result pre="Hospital, Angers, France 71 Seroconversion Among Staff at a Large" exact="Acute" post="Care Hospital in Denmark During the COVID-19 Pandemic Recruiting"/>
 <result pre="Paulo, SP, Brazil â€¢ Centro de Pesquisas ClÃ­nicas do Instituto" exact="Central" post="do Hospital das ClÃ­nicas da Faculdade de Medicina da"/>
 <result pre="Janeiro, Brazil 73 Gut Microbiota, â€œSpark and Flameâ€� of COVID-19" exact="Disease" post="Recruiting COVID-19 Other: exposure â€¢ Hospital CUF Infante Santo,"/>
 <result pre="Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria â€¢" exact="Infectious" post="Disease Hospital, Amanawa, Sokoto State, Nigeria â€¢ Murtala Muhammad"/>
 <result pre="Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria â€¢ Infectious" exact="Disease" post="Hospital, Amanawa, Sokoto State, Nigeria â€¢ Murtala Muhammad Speciaist"/>
 <result pre="China 80 Endovascular Thrombectomy in COVID-19 Infected Patients Completed Ischemic" exact="stroke" post="COVID-19 Other: mechanical trombectomy â€¢ Uhmontpellier, Montpellier, France 81"/>
 <result pre="ISGlobal, Barcelona, Spain 82 Evaluating Clinical Parameters of COVID-19 in" exact="Pregnancy" post="Not yet recruiting COVID-19 2019 novel coronavirus infection COVID-19"/>
 <result pre="COVID-19 in Pregnancy Not yet recruiting COVID-19 2019 novel coronavirus" exact="infection" post="COVID-19 infection â€¢ Chelsea and Westminster Hospital NHS Foundation"/>
 <result pre="Pregnancy Not yet recruiting COVID-19 2019 novel coronavirus infection COVID-19" exact="infection" post="â€¢ Chelsea and Westminster Hospital NHS Foundation Trust, London,"/>
 <result pre="Hospital NHS Foundation Trust, London, UK 83 Characteristics of COVID-19" exact="Infection" post="Among PREGnant Women Recruiting Coronavirus infection Pregnancy related Other:"/>
 <result pre="83 Characteristics of COVID-19 Infection Among PREGnant Women Recruiting Coronavirus" exact="infection" post="Pregnancy related Other: COVID-19 positive via testing â€¢ INOVA"/>
 <result pre="Characteristics of COVID-19 Infection Among PREGnant Women Recruiting Coronavirus infection" exact="Pregnancy" post="related Other: COVID-19 positive via testing â€¢ INOVA Health"/>
 <result pre="Church, VA, USA 84 Combination of Chest Scanography and Nasal" exact="Viral" post="Detection Test to Detect COVID-19 Positive Patients Before Surgical"/>
 <result pre="Biological: COVID-19 convalescent plasma (CCP) Biological: placebo â€¢ San Francisco" exact="General" post="Hospital, San Francisco, CA, USA â€¢ UCSF Medical Center"/>
 <result pre="recruiting COVID-19 Biological: anti-SARS-CoV-2 convalescent plasma 90 Influence of COVID-19" exact="Infection" post="in Thromboembolic Venous Disease: National Cohort Study Not yet"/>
 <result pre="National Cohort Study Not yet recruiting COVID-19 Other: deep venous" exact="disease" post="diagnostic â€¢ Red de Investigacion Vascular (SEACV), Madrid, Spain"/>
 <result pre="COVID-19 Other: deep venous disease diagnostic â€¢ Red de Investigacion" exact="Vascular" post="(SEACV), Madrid, Spain 91 Elmo Respiratory Support Project -"/>
 <result pre="â€¢ Red de Investigacion Vascular (SEACV), Madrid, Spain 91 Elmo" exact="Respiratory" post="Support Project - COVID-19 Not yet recruiting COVID-19 Respiratory"/>
 <result pre="Elmo Respiratory Support Project - COVID-19 Not yet recruiting COVID-19" exact="Respiratory" post="failure with hypoxia Other: Elmo Project at COVID-19: study"/>
 <result pre="Project - COVID-19 Not yet recruiting COVID-19 Respiratory failure with" exact="hypoxia" post="Other: Elmo Project at COVID-19: study in humans Device:"/>
 <result pre="usability 92 Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19" exact="Pneumonia" post="Recruiting COVID-19 pneumonia Drug: plasma from COVID-19 convalescent patient"/>
 <result pre="Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Recruiting COVID-19" exact="pneumonia" post="Drug: plasma from COVID-19 convalescent patient Drug: human immunoglobulin"/>
 <result pre="Device: MuscleSound Ultrasound Device: multifrequency bioimpedance spectroscopy â€¢ Duke University" exact="Medial" post="Center, Durham, NC, USA 95 Part Two of Novel"/>
 <result pre="Therapy with SARS- CoV-2 Specific T Cells in Patients with" exact="Severe" post="COVID-19 Recruiting COVID-19 Biological: SARS-CoV-2 specific T cells â€¢"/>
 <result pre="COVID-19 Recruiting COVID-19 Biological: SARS-CoV-2 specific T cells â€¢ Changi" exact="General" post="Hospital, Singapore, Singapore â€¢ KK Womenâ€™s and Childrenâ€™s Hospital,"/>
 <result pre="Singapore, Singapore â€¢ National University Hospital, Singapore, Singapore â€¢ Sengkang" exact="General" post="Hospital, Singapore, Singapore â€¢ Singapore General Hospital, Singapore, Singapore"/>
 <result pre="Singapore, Singapore â€¢ Sengkang General Hospital, Singapore, Singapore â€¢ Singapore" exact="General" post="Hospital, Singapore, Singapore 96 A Study Evaluating the Efficacy"/>
 <result pre="Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19" exact="Infection" post="Recruiting COVID-19 Biological: anti-SARS-CoV-2 convalescent plasma â€¢ Froedtert Hospital,"/>
 <result pre="97 Identification of Predictors for the Evolution of COVID-19 Related" exact="Pneumonia" post="by Transcriptomic and Seroproteomic Recruiting COVID-19 interstitial pneumonia â€¢"/>
 <result pre="COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic Recruiting COVID-19 interstitial" exact="pneumonia" post="â€¢ IRCCS Policlinico San Donato, San Donato Milanese, MI,"/>
 <result pre="IgG) in Patients Hospitalized for COVID-19 Not yet recruiting Coronavirus" exact="disease" post="2019 (COVID-19) Biological: COVID-19 convalescent plasma Biological: anti-COVID-19 human"/>
 <result pre="prevent and treat malaria, as well as to treat the" exact="autoimmune diseases" post="rheumatoid arthritis and lupus [44â€&quot;48]. Some preliminary reports have"/>
 <result pre="treat malaria, as well as to treat the autoimmune diseases" exact="rheumatoid arthritis" post="and lupus [44â€&quot;48]. Some preliminary reports have suggested that"/>
 <result pre="malaria, as well as to treat the autoimmune diseases rheumatoid" exact="arthritis" post="and lupus [44â€&quot;48]. Some preliminary reports have suggested that"/>
 <result pre="well as to treat the autoimmune diseases rheumatoid arthritis and" exact="lupus" post="[44â€&quot;48]. Some preliminary reports have suggested that hydroxychloroquine, alone"/>
 <result pre="recently launched study supported by NIHâ€™s National Heart, Lung and" exact="Blood" post="Institute, evaluating the safety and effectiveness of hydroxychloroquine for"/>
 <result pre="indicate that chloroquine and hydroxychloroquine have the potential to improve" exact="disease" post="outcomes and possibly slow COVID-19â€™s progression [49]. Other in"/>
 <result pre="antiviral action of hydroxychloroquine might be effective in limiting SARS-CoV-2" exact="infection" post="[49, 50]. Further, a combination of hydroxychloroquine and azithromycin"/>
 <result pre="several viruses including coronaviruses showing a strong impact on SARS-CoV" exact="infection" post="[52â€&quot;55]. Moreover, chloroquine and hydroxychloroquine are known to modulate"/>
 <result pre="hydroxychloroquine are known to modulate the immune response in some" exact="infectious diseases" post="via inhibition of autophagy, controlling Toll-like receptor (TLR) signaling,"/>
 <result pre="worked at both entry and post-entry stages of the COVID-19" exact="infection" post="[35]. Currently, we are looking for therapeutic strategies to"/>
 <result pre="infection. A preliminary clinical trial of chloroquine repurposing against SARS-CoV-2" exact="infection" post="has shown some positive results, which led to the"/>
 <result pre="alleged misconduct, hope, hype, and politicization that surrounds hydroxychloroquine, the" exact="malaria" post="drug touted as a COVID-19 treatment, a scientific picture"/>
 <result pre="in a fixed-dose combination for the treatment and prevention of" exact="HIV/AIDS" post="[60]. A recent study reported that the Î²-coronavirus viral"/>
 <result pre="of HIV/AIDS [60]. A recent study reported that the Î²-coronavirus" exact="viral" post="loads of a COVID-19 patient in Korea were significantly"/>
 <result pre="lopinavir/ritonavir treatment [61]. In contrast, another clinical trial on hospitalized" exact="adult" post="patients with severe COVID-19 shows no benefit with the"/>
 <result pre="SARS-CoV using vaccine candidates including inactivated virus, a live-attenuated virus," exact="viral" post="vectors, subunit vaccines, recombinant proteins, DNA vaccines, etc. across"/>
 <result pre="clinical trials of vaccines and candidate therapy for cytokine release" exact="syndrome" post="(CRS) against SARS-CoV-2 infection. Table 2 Current status of"/>
 <result pre="clinical trials of vaccines and candidate therapy for cytokine release" exact="syndrome" post="(CRS) against SARS-CoV-2 infectionÂ (Source: National Institute of Health,"/>
 <result pre="3 mRNA Zydus Cadila ZyCoV-D vaccine Phase 1/2 RNA recombinant" exact="measles" post="virus Mudoch Childreâ€™s Research Institute BCG vaccine Phase 2/3"/>
 <result pre="Vaccine Phase 1 Man-made mRNA Eli Lilly Treatment Phase 3" exact="Antibody" post="treatment GlaxoSmithkline+ Clover Biopharmaceuticals Vaccine Phase 1 Engineering adjuvants"/>
 <result pre="phase Plasma of treated patients Vir Biotechnology Treatment Phase 1" exact="Viral" post="replication inhibitor Ascletis Pharma Treatment Phase 1b Cocktail of"/>
 <result pre="titonavir Gamaleya Institute of Epidemiology and Microbiology Vaccine Phase 2" exact="Isolated" post="strain Siberian Vector Institute Vaccine Phase 1 Using a"/>
 <result pre="a strong defense against invasive pathogens. Recent studies demonstrated an" exact="acute" post="inflammation in the severely affected COVID-19 patients, leading to"/>
 <result pre="in the severely affected COVID-19 patients, leading to cytokine storm," exact="acute" post="respiratory distress, and then multiple organ failure. Nutritional interventions"/>
 <result pre="the severely affected COVID-19 patients, leading to cytokine storm, acute" exact="respiratory" post="distress, and then multiple organ failure. Nutritional interventions including"/>
 <result pre="a promising drug therapy against COVID-19. Fig. 3 Demonstration of" exact="viral" post="entry mechanisms and proposed therapeutic strategies against SARS-CoV-2. It"/>
 <result pre="speedy multiplication of virus resulting in the accumulation of monstrous" exact="viral" post="copies which in turn calls for a â€œsave the"/>
 <result pre="deploying and marching its armed forces to the site of" exact="infection" post="in the form of the cytokine storm syndrome. This"/>
 <result pre="to the site of infection. Thus, this likely stimulates the" exact="blood vessels" post="to leak out the immune cells in adjoining tissues,"/>
 <result pre="alveoli. Air sacs failing to exchange gases would lead to" exact="chronic" post="oxygen starvation which finally culminates in respiratory distress. Thus,"/>
 <result pre="would lead to chronic oxygen starvation which finally culminates in" exact="respiratory" post="distress. Thus, in almost 100% of cases, the first"/>
 <result pre="almost 100% of cases, the first critical clinical sign is" exact="respiratory" post="unrest which fits in the said hypothesis perfectly. Once"/>
 <result pre="unrest which fits in the said hypothesis perfectly. Once the" exact="blood vessels" post="lose their fluid, a sudden drop in blood pressure"/>
 <result pre="pressure is observed. This may probably be causing clogging of" exact="blood vessels" post="and clotting of blood in several tissues leading to"/>
 <result pre="category which includes people with an impaired immune system, a" exact="chronic" post="respiratory condition, cancer, etc. who cannot afford a competent"/>
 <result pre="which includes people with an impaired immune system, a chronic" exact="respiratory" post="condition, cancer, etc. who cannot afford a competent immune"/>
 <result pre="triggers them. In the first few days of catching any" exact="infection" post="majorly, natural killer cells and macrophages take charge in"/>
 <result pre="of concern to note that in COVID-19 patients succumbing to" exact="heart" post="attack, IL-6 prevented the activity of STAT-5 signal transducer,"/>
 <result pre="immunoglobulin-like receptor genes (KIR genes) and therefore can contain the" exact="infection" post="in the initial stage itself. Thus, Indian populations are"/>
 <result pre="stage itself. Thus, Indian populations are less susceptible to these" exact="infections" post="and also confer Indians with stronger immunity against other"/>
 <result pre="and also confer Indians with stronger immunity against other viruses," exact="autoimmune diseases," post="and even tumors [67]. However, recently, this claim was"/>
 <result pre="is utmost required to develop adaptive immunity to fight upcoming" exact="viral" post="infections. Thus, today, countries vie with each other for"/>
 <result pre="lung tissue can be instrumental in discovering effective drugs against" exact="viral" post="entry since this gene deals with the production of"/>
 <result pre="Any defect or overexpression of this gene may either prevent" exact="viral" post="entry into the host cell or may make it"/>
 <result pre="at an advantage since it made some people immune to" exact="HIV infection" post="by preventing viral entry. One of the observed trends"/>
 <result pre="an advantage since it made some people immune to HIV" exact="infection" post="by preventing viral entry. One of the observed trends"/>
 <result pre="it made some people immune to HIV infection by preventing" exact="viral" post="entry. One of the observed trends in COVID-19 is"/>
 <result pre="and who is more prone to such deadly viruses. The" exact="viral" post="genomics and proteomics studies would help to discover some"/>
 <result pre="by some inhibitor molecules that would halt the process of" exact="viral" post="multiplication. MicroRNA, a Direct Attack on the Viral Genome"/>
 <result pre="would halt the process of viral multiplication. MicroRNA, a Direct" exact="Attack" post="on the Viral Genome The miRNAs are small, non-coding,"/>
 <result pre="process of viral multiplication. MicroRNA, a Direct Attack on the" exact="Viral" post="Genome The miRNAs are small, non-coding, single-stranded RNA molecules,"/>
 <result pre="including RNA silencing, post-transcriptional regulators of gene expression involved in" exact="cardiovascular" post="development and health [70â€&quot;75]. Several thousand human genes, amounting"/>
 <result pre="studies have been used to interpret which host microRNAs have" exact="complete" post="complementarity with viral RNA so that viral RNA expression"/>
 <result pre="used to interpret which host microRNAs have complete complementarity with" exact="viral" post="RNA so that viral RNA expression can be silenced."/>
 <result pre="host microRNAs have complete complementarity with viral RNA so that" exact="viral" post="RNA expression can be silenced. Recently, microRNA-5197-3p has been"/>
 <result pre="as the most valuable site for interaction with SARS-CoV-2, and" exact="complete" post="complementary miRNA regions in the viral genome have been"/>
 <result pre="interaction with SARS-CoV-2, and complete complementary miRNA regions in the" exact="viral" post="genome have been predicted. This proposed site lacks any"/>
 <result pre="host target specific genes of the virus and interfere with" exact="viral" post="molecular processes vital for reproduction, namely replication, protein synthesis,"/>
 <result pre="expression. Thus, microRNAs are vital tools for tailoring and silencing" exact="viral" post="genome as these complementarily bind to the viral genome"/>
 <result pre="and silencing viral genome as these complementarily bind to the" exact="viral" post="genome and prevent their expression. It has been found"/>
 <result pre="has been genetically engineered using weakened common cold adenovirus (ChAdOx1)" exact="infective" post="only to chimpanzees. Genes coding for spike glycoprotein (S)"/>
 <result pre="within 28Â days of its administration. It also drastically reduced" exact="respiratory" post="distress in the patients and also prevented viral replication."/>
 <result pre="drastically reduced respiratory distress in the patients and also prevented" exact="viral" post="replication. Its human trials are in the process, and"/>
 <result pre="natural immune system. This molecule would be effective against other" exact="viral" post="diseases like influenza. It is currently under phase I"/>
 <result pre="led to â€œcytokine stormâ€� and which finally ended up in" exact="heart" post="failure due to stimulation of the coagulation process. Also,"/>
 <result pre="antiviral drug on COVID-19 patients. NVX-CoV2373 Vaccine The Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI) has agreed to fund $384m to"/>
 <result pre="of COVID-19 vaccine which would boost rapid production of antibodies." exact="Antibody" post="Cocktail COVI-SHIELD Some researchers at Mount Sinai Health System"/>
 <result pre="the AXL kinase protein and was originally developed to prevent" exact="cancer" post="cell metastasis. It has been proposed to use this"/>
 <result pre="cell in the first stage and controlling the progression of" exact="disease" post="in patients already suffering from COVID-19. Thus, it is"/>
 <result pre="conducting a clinical trial that shows that BCG vaccine reduces" exact="viral" post="infections. It is estimated to be tried on more"/>
 <result pre="Therefore, a dead virus simply means the one in which" exact="infective" post="capacity is removed off so that they cannot enter"/>
 <result pre="so they do not prove very effective. Examples are flu," exact="hepatitis" post="A, etc. Attenuated Virus Vaccine Such viruses are more"/>
 <result pre="effects post-treatment. Some of the examples are rotavirus, measles, mumps," exact="rubella" post="(MMR combined vaccine), smallpox, etc. Thus, both live and"/>
 <result pre="live and attenuated vaccines train our body to fight against" exact="infection" post="as they are more natural. Some of the limitations"/>
 <result pre="in the light of a known pathogen, e.g., Haemophilus influenzae" exact="type B" post="(Hib). Nucleic Acid Vaccines In this approach, DNA from"/>
 <result pre="in laboratories at low cost; do not allow lysogeny of" exact="viral" post="genes into host genes; and can trigger an immune"/>
 <result pre="an immune response by infecting dendritic cells and target both" exact="systemic" post="and mucosal immune response. Johnson and Johnson, a US-based"/>
 <result pre="a major challenge. Currently, we are fighting a twenty-first century" exact="disease" post="with twentieth century weapons. The clinical trials of repurposing"/>
 <result pre="of repurposing the existing antiviral agents against this potentially fatal" exact="disease" post="are going on across the world. Recently, several possibilities"/>
 <result pre="going on across the world. Recently, several possibilities including targeting" exact="viral" post="binding receptors (ACE2) and spike proteins, stimulating an immune"/>
 <result pre="is facing a challenge in dealing with a new coronavirus" exact="infection" post="that has just emerged in humans and we are"/>
 <result pre="pandemic). We would be witnessing many new and far deadly" exact="viral" post="pandemics in the ensuing time, and thus, we really"/>
 <result pre="NIH grant AG063162 (to AR). We acknowledge support from the" exact="Central" post="University of Punjab, Bathinda, India. We thank all the"/>
 <result pre="Der WerfSBrodtH-RBeckerSRabenauHPanningMKolesnikovaLFouchierRAIdentification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN Engl J Med2003348201967197612690091 3.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWA novel coronavirus associated"/>
 <result pre="WerfSBrodtH-RBeckerSRabenauHPanningMKolesnikovaLFouchierRAIdentification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN Engl J Med2003348201967197612690091 3.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWA novel coronavirus associated with"/>
 <result pre="syndromeN Engl J Med2003348201967197612690091 3.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWA novel coronavirus associated with severe" exact="acute" post="respiratory syndromeN Engl J Med2003348201953196612690092 4.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a"/>
 <result pre="Engl J Med2003348201967197612690091 3.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySTongSUrbaniCComerJALimWA novel coronavirus associated with severe acute" exact="respiratory" post="syndromeN Engl J Med2003348201953196612690092 4.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel"/>
 <result pre="4.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med2012367191814182023075143 5.HuangCWangYLiXRenLZhaoJHuYZhangLFanGXuJGuXClinical features of"/>
 <result pre="World Health OrganizationWHO guidelines for the global surveillance of severe" exact="acute" post="respiratory syndrome (SARS): updated recommendations, October 20042004GenevaWorld Health Organization"/>
 <result pre="Health OrganizationWHO guidelines for the global surveillance of severe acute" exact="respiratory" post="syndrome (SARS): updated recommendations, October 20042004GenevaWorld Health Organization 7.MeoSAAlhowikanAMAl-KhlaiwiTMeoIMHalepotoDMIqbalMUsmaniAMHajjarWAhmedNNovel"/>
 <result pre="OrganizationWHO guidelines for the global surveillance of severe acute respiratory" exact="syndrome" post="(SARS): updated recommendations, October 20042004GenevaWorld Health Organization 7.MeoSAAlhowikanAMAl-KhlaiwiTMeoIMHalepotoDMIqbalMUsmaniAMHajjarWAhmedNNovel coronavirus"/>
 <result pre="Rev Microbiol201917318119230531947 9.GuoYRCaoQDHongZSTanYYChenSDJinHJTanKSWangDYYanYThe origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the statusMilitary"/>
 <result pre="an update on the statusMilitary Med Res20207111 10.ChanJF-WYuanSKokK-Hcollab: To KK-WChuHYangJXingFLiuJYipCC-YPoonRW-SA" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="the statusMilitary Med Res20207111 10.ChanJF-WYuanSKokK-Hcollab: To KK-WChuHYangJXingFLiuJYipCC-YPoonRW-SA familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="coronavirusâ€&quot;infected pneumoniaN Engl J Med20203821199120731995857 12.World Health Organization (2020) Coronavirus" exact="disease" post="(COVID-19) outbreak. URL https://www.whoint/emergencies/diseases/novel-coronavirus-2019 Accessed March 13.MeoSAlhowikanAAl-KhlaiwiTMeoIHalepotoDIqbalMUsmaniAHajjarWAhmedNNovel coronavirus 2019-nCoV:"/>
 <result pre="MERS-CoVEur Rev Med Pharmacol Sci20202442012201932141570 14.World Health Organization (2020) Coronavirus" exact="disease" post="2019 (COVID-19): situation report, 194 (1st Aug 2020). 15.HuangCWangYLiXRenLZhaoJHuYZhangLFanGXuJGuXChengZYuTXiaJWeiYWuWXieXYinWLiHLiuMXiaoYGaoHGuoLXieJWangGJiangRGaoZJinQWangJCaoBClinical"/>
 <result pre="Treatment Expert Group for C (2020) Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med 10.1056/NEJMoa2002032, 382,"/>
 <result pre="glucose control and outcomes in patients with COVID-19 and pre-existing" exact="type 2" post="diabetesCell Metab20203110681077.e332369736 24.LiXXuSYuMWangKTaoYZhouYShiJZhouMWuBYangZZhangCYueJZhangZRenzHLiuXXieJXieMZhaoJRisk factors for severity and mortality in"/>
 <result pre="2 diabetesCell Metab20203110681077.e332369736 24.LiXXuSYuMWangKTaoYZhouYShiJZhouMWuBYangZZhangCYueJZhangZRenzHLiuXXieJXieMZhaoJRisk factors for severity and mortality in" exact="adult" post="COVID-19 inpatients in WuhanJ Allergy Clin Immunol202014611011832294485 25.ChenJPathogenicity and"/>
 <result pre="2 is a functional receptor for the SARS coronavirusNature2003426696545045414647384 28.LiGFanYLaiYHanTLiZZhouPPanPWangWHuDLiuXZhangQWuJCoronavirus" exact="infections" post="and immune responsesJ Med Virol202092442443231981224 29.ChanJFKokKHZhuZChuHcollab: To KKYuanSYuenKYGenomic characterization"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 30.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRCoronavirus susceptibility to the"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 30.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRCoronavirus susceptibility to the"/>
 <result pre="patient with atypical pneumonia after visiting WuhanEmerg Microbes Infect20209122123631987001 30.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRCoronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio201892e00221-0021829511076 31.RenLLWangYMWuZQXiangZCGuoLXuTJiangYZXiongYLiYJLiXWLiHFanGHGuXYXiaoYGaoHXuJYYangFWangXMWuCChenLLiuYWLiuBYangJWangXRDongJLiLHuangCLZhaoJPHuYChengZSLiuLLQianZHQinCJinQCaoBWangJWIdentification of a novel"/>
 <result pre="the proofreading exoribonucleasemBio201892e00221-0021829511076 31.RenLLWangYMWuZQXiangZCGuoLXuTJiangYZXiongYLiYJLiXWLiHFanGHGuXYXiaoYGaoHXuJYYangFWangXMWuCChenLLiuYWLiuBYangJWangXRDongJLiLHuangCLZhaoJPHuYChengZSLiuLLQianZHQinCJinQCaoBWangJWIdentification of a novel coronavirus causing severe" exact="pneumonia" post="in human: a descriptive studyChin Med J20201331015102432004165 32.LuRZhaoXLiJNiuPYangBWuHWangWSongHHuangBZhuNBiYMaXZhanFWangLHuTZhouHHuZZhouWZhaoLChenJMengYWangJLinYYuanJXieZMaJLiuWJWangDXuWHolmesECGaoGFWuGChenWShiWTanWGenomic characterisation"/>
 <result pre="Antimicrob Agents:105932. 10.1016/j.ijantimicag.2020.105932 38.GuastalegnameMValloneACould chloroquine /hydroxychloroquine be harmful in coronavirus" exact="disease" post="2019 (COVID-19) treatment?Clin Infect Dis20207188888932211771 39.BrownAJWonJJGrahamRLDinnonKHIIISimsACFengJYCihlarTDenisonMRBaricRSSheahanTPBroad spectrum antiviral remdesivir"/>
 <result pre="42.MulanguSDoddLEDaveyRTJrTshiani MbayaOProschanMMukadiDLusakibanza ManzoMNzoloDTshomba OlomaAIbandaAA randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med2019381242293230331774950 43.LiGDe ClercqETherapeutic options for the"/>
 <result pre="and pharmacological properties of hydroxychloroquine and chloroquine in treatment of" exact="systemic" post="lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases"/>
 <result pre="pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic" exact="lupus erythematosus," post="rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines"/>
 <result pre="of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus," exact="rheumatoid arthritis" post="and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic"/>
 <result pre="hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid" exact="arthritis" post="and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic"/>
 <result pre="rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in" exact="systemic" post="lupus erythematosus and rheumatoid arthritis patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria"/>
 <result pre="arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic" exact="lupus erythematosus" post="and rheumatoid arthritis patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin"/>
 <result pre="diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and" exact="rheumatoid arthritis" post="patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin Rev Allergy Immunol201242214515321221847"/>
 <result pre="45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid" exact="arthritis" post="patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin Rev Allergy Immunol201242214515321221847"/>
 <result pre="in systemic lupus erythematosus and rheumatoid arthritis patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from" exact="malaria" post="to autoimmunityClin Rev Allergy Immunol201242214515321221847 47.GladmanDDUrowitzMBSenecalJLFortinPJPettyREEsdaileJMCarretteSEdworthySMSmithCDThorneJCAspects of use of"/>
 <result pre="autoimmunityClin Rev Allergy Immunol201242214515321221847 47.GladmanDDUrowitzMBSenecalJLFortinPJPettyREEsdaileJMCarretteSEdworthySMSmithCDThorneJCAspects of use of antimalarials in" exact="systemic" post="lupus erythematosusJ Rheumatol19982559839859598902 48.TaylorJKMcMurrayRVMedical therapy for systemic lupus erythematosusJ"/>
 <result pre="Rev Allergy Immunol201242214515321221847 47.GladmanDDUrowitzMBSenecalJLFortinPJPettyREEsdaileJMCarretteSEdworthySMSmithCDThorneJCAspects of use of antimalarials in systemic" exact="lupus" post="erythematosusJ Rheumatol19982559839859598902 48.TaylorJKMcMurrayRVMedical therapy for systemic lupus erythematosusJ Miss"/>
 <result pre="of antimalarials in systemic lupus erythematosusJ Rheumatol19982559839859598902 48.TaylorJKMcMurrayRVMedical therapy for" exact="systemic" post="lupus erythematosusJ Miss State Med Assoc2011522394321387869 49.LiuJCaoRXuMWangXZhangHHuHLiYHuZZhongWWangMHydroxychloroquine, a less"/>
 <result pre="antimalarials in systemic lupus erythematosusJ Rheumatol19982559839859598902 48.TaylorJKMcMurrayRVMedical therapy for systemic" exact="lupus" post="erythematosusJ Miss State Med Assoc2011522394321387869 49.LiuJCaoRXuMWangXZhangHHuHLiYHuZZhongWWangMHydroxychloroquine, a less toxic"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061632194981 50.YaoXYeFZhangMCuiCHuangBNiuPLiuXZhaoLDongESongCZhanSLuRLiHTanWLiuDIn vitro antiviral activity and projection"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis20207173273932150618 51.Gautret P,"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis20207173273932150618 51.Gautret P, Lagier"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis20207173273932150618 51.Gautret P, Lagier JC,"/>
 <result pre="Agents:105949. 10.1016/j.ijantimicag.2020.105949 52.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J200526916115318 53.RolainJMColsonPRaoultDRecycling of chloroquine and its hydroxyl"/>
 <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral" post="infections in the 21st centuryInt J Antimicrob Agents200730429730817629679 54.Devaux"/>
 <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infections" post="in the 21st centuryInt J Antimicrob Agents200730429730817629679 54.Devaux CA,"/>
 <result pre="COVID-19? Int J Antimicrob Agents:105938. 10.1016/j.ijantimicag.2020.105938 55.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases?Lancet Infect Dis200331172272714592603"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCR. J Korean Med Sci 35(6)"/>
 <result pre="for therapyEndocr Rev201738214516828323921 74.Song R, Hu XQ, Zhang L (2019)" exact="Mitochondrial" post="MiRNA in cardiovascular function and disease. Cells 8(12). 10.3390/cells8121475"/>
 <result pre="74.Song R, Hu XQ, Zhang L (2019) Mitochondrial MiRNA in" exact="cardiovascular" post="function and disease. Cells 8(12). 10.3390/cells8121475 75.CaoQChenXMHuangCPollockCAMicroRNA as novel"/>
 <result pre="RooijETherapeutic inhibition of miR-208a improves cardiac function and survival during" exact="heart" post="failureCirculation2011124141537154721900086 78.DickinsonBASemusHMMontgomeryRLStackCLatimerPALewtonSMLynchJMHullingerTGSetoAGvan RooijEPlasma microRNAs serve as biomarkers of therapeutic"/>
 <result pre="78.DickinsonBASemusHMMontgomeryRLStackCLatimerPALewtonSMLynchJMHullingerTGSetoAGvan RooijEPlasma microRNAs serve as biomarkers of therapeutic efficacy and" exact="disease" post="progression in hypertension-induced heart failureEur J Heart Fail201315665065923388090 79.PintiMVHathawayQAHollanderJMRole"/>
 <result pre="as biomarkers of therapeutic efficacy and disease progression in hypertension-induced" exact="heart" post="failureEur J Heart Fail201315665065923388090 79.PintiMVHathawayQAHollanderJMRole of microRNA in metabolic"/>
 <result pre="therapeutic efficacy and disease progression in hypertension-induced heart failureEur J" exact="Heart" post="Fail201315665065923388090 79.PintiMVHathawayQAHollanderJMRole of microRNA in metabolic shift during heart"/>
 <result pre="J Heart Fail201315665065923388090 79.PintiMVHathawayQAHollanderJMRole of microRNA in metabolic shift during" exact="heart" post="failureAm J Phys Heart Circ Phys20173121H33H45 80.TanakaTNarazakiMKishimotoTImmunotherapeutic implications of"/>
 <result pre="of microRNA in metabolic shift during heart failureAm J Phys" exact="Heart" post="Circ Phys20173121H33H45 80.TanakaTNarazakiMKishimotoTImmunotherapeutic implications of IL-6 blockade for cytokine"/>
 <result pre="Agents:105982 10.1016/j.ijantimicag.2020.105982 82.MichotJMAlbigesLChaputNSaadaVPommeretFGriscelliFBalleyguierCBesseBMarabelleANetzerFMeradMRobertCBarlesiFGachotBStoclinATocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related" exact="respiratory" post="failure: a case reportAnn Oncol20203196196432247642"/>
</results>
